413 related articles for article (PubMed ID: 10882607)
1. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
2. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
Kretschmar M; Nichterlein T; Hannak D; Hof H
Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
4. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
5. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
[TBL] [Abstract][Full Text] [Related]
9. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes).
Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T
Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
Andes D; Stamsted T; Conklin R
Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
[TBL] [Abstract][Full Text] [Related]
11. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
12. [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].
Chavanet P; Charlier N; Brenet A; Goux A; Muggéo E; Caillot D; Casasnovas O; Kistermann JP; Waldner A; Portier H
Pathol Biol (Paris); 1992 May; 40(5):507-12. PubMed ID: 1495835
[TBL] [Abstract][Full Text] [Related]
13. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
Legrand P; Chéron M; Leroy L; Bolard J
J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
[TBL] [Abstract][Full Text] [Related]
14. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis.
Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J
Int J Antimicrob Agents; 2009 Dec; 34(6):566-9. PubMed ID: 19733036
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
17. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
18. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.
Louie A; Kaw P; Banerjee P; Liu W; Chen G; Miller MH
Antimicrob Agents Chemother; 2001 Feb; 45(2):485-94. PubMed ID: 11158745
[TBL] [Abstract][Full Text] [Related]
19. Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans.
An M; Shen H; Cao Y; Zhang J; Cai Y; Wang R; Jiang Y
Int J Antimicrob Agents; 2009 Mar; 33(3):258-63. PubMed ID: 19095412
[TBL] [Abstract][Full Text] [Related]
20. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
Adler-Moore JP; Olson JA; Proffitt RT
J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]